Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SALIMAH CUMBER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1912011966
CMS profile
268138
Location
HOUSTON, TX

General Payments · PY2018–2024

$5,213.23

  • Reported across 368 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$490.29

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $490.29 14

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $387.95 8
ABBVIE INC. $57.48 3
Nevro Corp. $15.34 1
Amgen Inc. $15.11 1
GlaxoSmithKline, LLC. $14.41 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $847.97 82
PY2019 $625.63 64
PY2020 $1,102.31 63
PY2021 $1,437.22 98
PY2022 $412.71 32
PY2023 $297.10 15
PY2024 $490.29 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $16.78 02/27/2024 Food and Beverage Undisputed 01/23/2026 1103521540 CMS
ABBVIE INC. $19.62 03/26/2024 Food and Beverage Undisputed 01/23/2026 1103521542 CMS
ABBVIE INC. $21.08 10/01/2024 Food and Beverage Undisputed 01/23/2026 1103521544 CMS
Amgen Inc. $15.11 02/05/2024 Food and Beverage Undisputed 01/23/2026 1117534456 CMS
AstraZeneca Pharmaceuticals LP $16.63 01/16/2024 Food and Beverage Undisputed 01/23/2026 1104201627 CMS
AstraZeneca Pharmaceuticals LP $125.01 01/31/2024 Food and Beverage Undisputed 01/23/2026 1104276099 CMS
AstraZeneca Pharmaceuticals LP $153.99 02/13/2024 Food and Beverage Undisputed 01/23/2026 1105595301 CMS
AstraZeneca Pharmaceuticals LP $24.26 03/13/2024 Food and Beverage Undisputed 01/23/2026 1104508044 CMS
AstraZeneca Pharmaceuticals LP $16.71 07/16/2024 Food and Beverage Undisputed 01/23/2026 1105640834 CMS
AstraZeneca Pharmaceuticals LP $3.91 09/17/2024 Food and Beverage Undisputed 01/23/2026 1104619062 CMS
AstraZeneca Pharmaceuticals LP $30.20 09/17/2024 Food and Beverage Undisputed 01/23/2026 1105533566 CMS
AstraZeneca Pharmaceuticals LP $17.24 11/19/2024 Food and Beverage Undisputed 01/23/2026 1105589172 CMS
GlaxoSmithKline, LLC. $14.41 02/27/2024 Food and Beverage Undisputed 01/23/2026 1116382362 CMS
Nevro Corp. $15.34 10/22/2024 Food and Beverage Undisputed 01/23/2026 1130765966 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.